Inflammatory lesions of the peritoneum mimic carcinomatosis after treatment with intravenous chemotherapy and intraperitoneal catumaxomab

Journal of Clinical Oncology

Volumn 29, Issue 22, 2011, Pages

  Rüssel, Jörn ^a   Stein, Alexander ^a   Behrmann, Curd ^a   Hauptmann, Steffen ^a   Krummenerl, Patrick ^a   Schmoll, Hans Joachim ^a   Arnold, Dirk ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CATUMAXOMAB; CISPLATIN; EPIRUBICIN; BISPECIFIC ANTIBODY;

ADULT; ANAMNESIS; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CARCINOMATOSIS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; GASTRECTOMY; GASTROSCOPY; HISTOPATHOLOGY; HUMAN; INFLAMMATION; LAPAROSCOPY; MALE; MULTIPLE CYCLE TREATMENT; PERITONEAL CARCINOMATOSIS; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; CARCINOMA; CHEMICALLY INDUCED DISORDER; DIFFERENTIAL DIAGNOSIS; INFUSION; INTRAOPERATIVE PERIOD; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; MIDDLE AGED; PATHOLOGY; PERITONEUM TUMOR; PERITONITIS; PHASE 2 CLINICAL TRIAL (TOPIC); POSTOPERATIVE PERIOD; STOMACH TUMOR; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTIBODIES, BISPECIFIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE II AS TOPIC; DIAGNOSIS, DIFFERENTIAL; GASTRECTOMY; HUMANS; INFUSIONS, INTRAVENOUS; INFUSIONS, PARENTERAL; INTRAOPERATIVE PERIOD; MALE; MIDDLE AGED; NEOPLASM STAGING; PERITONEAL NEOPLASMS; PERITONITIS; POSTOPERATIVE PERIOD; STOMACH NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 80051647524     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.34.3939     Document Type: Article

References (11)

1. Sugarbaker PH, Yonemura Y: Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: Best palliation with a ray of hope for cure. Oncology 58:96-107, 2000 (Pubitemid 30113860)
2. Cunningham D, Allum WH, Stenning SP, et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11-20, 2006
3. Went P, Vasei M, Bubendorf L, et al: Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 94:128-135, 2006 (Pubitemid 43088552)
4. Zeidler R, Reisbach G, Wollenberg B, et al: Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 163:1246-1252, 1999 (Pubitemid 29352740)
5. Parsons S, Murawa PX, Koralewski P, et al: Intraperitoneal treatment of malignant ascites due to epithelial tumors with catumaxomab: A phase II/III study. J Clin Oncol 26:132s, 2008 (suppl; abstr 3000)
6. Jeyarajah DR, Thistlethwaite JR Jr: General aspects of cytokine-release syndrome: Timing and incidence of symptoms. Transplant Proc 25:16-20, 1993 (Pubitemid 23115816)
7. Kubicka U, Olszewski WL, Tarnowski W, et al: Normal human immune peritoneal cells: Subpopulations and functional characteristics. Scand J Immunol 44:157-163, 1996 (Pubitemid 26246735)
8. Burges A, Wimberger P, Kümper C, et al: Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: A phase I/II study. Clin Cancer Res 13:3899-3905, 2007 (Pubitemid 47037597)
9. Molema G, Tervaert JW, Kroesen BJ, et al: CD3 directed bispecific antibodies induce increased lymphocyte-endothelial cell interactions in vitro. Br J Cancer 82:472-479, 2000 (Pubitemid 30045400)
10. Saenger YM, Wolchok JD: The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: Patient cases. Cancer Immun 8:1, 2008
11. Yuan J, Page DB, Ku GY, et al: Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy. Cancer Immun 10:1, 2010